Immunocore now expects TAB-AM phase three data in Q2, after previously saying as early as the end of the year. The company completed enrollment last quarter, which gave more insight into how events are accruing.
IMCR · Immunocore Holdings plc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 20%
- Last earnings
- Aug 6, 2026
- Latest filing
- 10-Q · Nov 6
- Price history
- Feb 2021 to Nov 2026
Up next
Latest documents
Immunocore Holdings plc generated $324.8 million in KIMMTRAK revenue for the nine months ended September 30, 2026, up 9.9%, while cash reached $512.2 million. Existing liquidity and anticipated KIMMTRAK revenue should fund operations for at least twelve months.
Immunocore Holdings plc reported KIMMTRAK net revenues of $102.2 million in Q3 2026, while the Phase 3 TEBE-AM trial reached 540 patients; topline overall survival data are expected in the second quarter of 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| dose | 1,200 | as of the date of the release | — |
| evaluable patients | 17 | As of June 2026 | — |
| mDoR | 24.1 | As of June 2026 | — |
| median duration of response (mDoR) | 14.5 | As of June 2026 | — |
| median OS | 20.3 | As of June 2026 | — |
| median progression-free survival (mPFS) | 4.2 | As of June 2026 | — |
| mPFS | 8.1 | As of June 2026 | — |
| overall response rate (ORR) | 19% | As of June 2026 | — |
| partnered revenue | $9.9M | the three months ended September 30, 2026 filing | — |
| patients still on study | 10 | As of June 2026 | — |
| target enrollment | 540 | as of the date of the release | — |
| two-year OS rate | 70% | As of June 2026 | — |
| Control arm five-year overall survival rate | 8% | five years | — |
| KIMMTRAK five-year overall survival rate | 16% | five years | — |
| KIMMTRAK net product sales growth | 16% | the six months ended June 30, 2026 | — |
| Mean duration of treatment | 14 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMCR
this stock
Immunocore Holdings plc
|
$1.36B | -23.9% | +43.1% | — | 15.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 17
Immunocore now expects TAB-AM phase three data in Q2, after previously saying as early as the end of the year. The company completed enrollment last quarter, which gave more insight into how events are accruing.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMCR | -11.8% | -14.8% | -10.7% | -13.4% | -23.9% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -3.2% | -5.5% | -1.5% | -4.7% | -25.1% |